Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.33 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.30 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.30 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488921 | 0.93 | DNM1 (0.45) | DNM1ALDH1A1CNR1CNR2ADRB2 | |
| SCHEMBL4498566 | 0.93 | DNM1 (0.50) | DNM1ALDH1A1CNR1CNR2LPAR1 | |
| SCHEMBL27900394 | 0.91 | DNM1 (0.48) | DNM1ALDH1A1CNR1CNR2LPAR1 | |
| SCHEMBL4490936 | 0.91 | DNM1 (0.42) | DNM1ALDH1A1CNR1CNR2ADRB2 | |
| SCHEMBL4494948 | 0.91 | DNM1 (0.38) | DNM1ALDH1A1CNR1CNR2 | |
| SCHEMBL4495268 | 0.89 | DNM1 (0.50) | DNM1ALDH1A1CNR1CNR2LPAR1 | |
| SCHEMBL2790768 | 0.89 | DNM1 (0.41) | DNM1ALDH1A1CNR1CNR2ADRB2 | |
| SCHEMBL28474626 | 0.88 | DNM1 (0.37) | DNM1ALDH1A1CNR1CNR2 | |
| SCHEMBL28019342 | 0.87 | DNM1 (0.53) | DNM1ALDH1A1CNR1CNR2LPAR1 | |
| SCHEMBL27883017 | 0.85 | DNM1 (0.34) | DNM1LPAR1LPAR3LPAR2LPAR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655291-B1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| CN-103130739-B | There is the compound of thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2015-09-16 | — | — | CN | disclosed |
| CN-102796058-B | Compound having thrombopoietin receptor agonism | SHIONOGI & CO | 2015-05-13 | — | — | CN | disclosed |
| CN-103130739-A | Compounds having thrombopoietin receptor agonism | SHIONOGI & CO | 2013-06-05 | — | — | CN | disclosed |
| CN-102796058-A | Compound having thrombopoietin receptor agonism | SHIONOGI & CO | 2012-11-28 | — | — | CN | disclosed |
| CN-102208681-B | Nonaqueous electrolyte solution and lithium secondary battery using same | MITSUBISHI CHEM CORP | 2012-11-21 | — | — | CN | disclosed |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| US-7601746-B2 | Compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| CN-1863783-A | Compounds with Thrombopoietin Receptor Agonism | SHIONOGI & CO (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
| US-4112024-A | PESTICIDES | EXXON RESEARCH & ENGINEERING CO. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4003939-A | PESTICIDES | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | MPL, TEK, GHRHR | DNM1 3781/4885ALDH1A1 2953/4885CNR1 172/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | DNM1 2139/4885ALDH1A1 10/4885CNR1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.